/

EVAX

Evaxion A/SClosed

2.76−0.24 −8.00%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delayAfter hours 2.73 −0.95%

Open

2.98

Prev close

3.00

Day range

2.722.99

52-week range

2.7212.15

Volume

133.40K0.65×

Mkt cap

24.90M

P/E ttm

—

Fwd P/E

-184.00

EPS ttm

-1.00

Div yield

0.00%

Earnings

—

From 52w high

−77.28%

Price Chart

Yahoo Finance · delayed

EVAXOct 13, 2026O 2.98H 2.99L 2.72C 2.76−0.24 (−8.00%)Vol 133.80K

SMA 503.15
SMA 2003.62

1Y change −55.91% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

EVAX Evaxion A/S · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −12.66%
1 month: −11.82%
3 months: −8.91%
6 months: −33.33%
Year to date: −42.14%
1 year: −55.91%

Valuation & ownership

Market cap: 24.90M
Enterprise value: 16.12M
P/E (ttm): —
Forward P/E: -184.00
PEG ratio: —
Price / book: 2.41
Price / sales (ttm): 3.32
EV / EBITDA: -1.94
EPS (ttm): -1.00
EPS (forward): -0.0150
Beta (5y monthly): 0.51
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 9.02M
Float: 5.68M
Short % of float: 0.67%
Short ratio (days): 1.06
Held by insiders: 16.15%
Held by institutions: 9.42%
Avg volume (3m): 203.99K
50-day average: 3.15
200-day average: 3.63
52-week change: −55.91%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): oversold 29.1
vs 50-day SMA: −12.31%
vs 200-day SMA: −23.66%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 6.01%
Realised vol (20d, ann.): 45.9%
From 52-week high: −77.28%
From 52-week low: +1.47%

ANR

Analyst Consensus

4 analysts

Consensus

Strong buy

1.25 on a 1 (strong buy) – 5 (sell) scale

Mean target

11.25

+307.61% implied

Low 9.00Median 10.00High 16.00

Recommendation trend

Now4 / 0 / 0
1m ago4 / 0 / 0

Buy / hold / sell counts

DES

About Evaxion A/S

Yahoo Finance profile

Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin and soft tissue infections with S. aureus bacteria; EVX-B2 to target multi-component prophylactic vaccine against gonorrhea bacteria; EVX-B3 to target bacterial pathogen associated with repeated infections; and EVX-V1, a multi-component prophylactic vaccine candidate for cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark.

Sector: Healthcare
Industry: Biotechnology
Employees: 46
Headquarters: Horsholm, Denmark
Website: evaxion.ai
Officers: Dr. Helen Katrina Tayton-Martin MBA, Ph.D. Chief Executive Officer
Mr. Andreas Holm Mattsson M.Sc. Founder & Chief AI Officer
Mr. Thomas Frederik Schmidt M.Sc. Chief Financial Officer

SEAS

Seasonality · EVAX

2021–2026 · monthly returns

Strongest month Sep +19.72%Weakest month Jan −30.71%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-33.3	-0.6	17.7	18.5	-9.3	-22.5	-9.0	6.4	9.3	-15.9			−42.1%
2025	-41.9	-21.0	-4.6	-17.3	60.8	-0.4	9.4	2.6	36.7	52.9	3.2	-19.6	+12.9%
2024	-42.7	-8.4	-11.1	30.3	-12.0	-21.0	-2.8	8.2	2.0	-14.1	-37.8	-49.1	−87.7%
2023	-9.3	-4.3	-26.6	11.5	20.6	-13.8	-5.3	-33.1	0.4	34.5	-28.7	-14.1	−61.4%
2022	-29.0	-3.2	-0.3	-7.6	-30.0	-2.0	59.4	-23.2	11.9	-1.1	-16.2	-18.6	−59.8%
2021			-15.5	20.8	-5.5	14.8	-30.2	20.9	47.6	-21.1	-38.8	-5.2	−36.7%

13F

Investors Holding EVAX

latest 13F filings of 29 followed managers

Investors holding EVAX
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$104.8K	0.00%	33.80K	−14%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

EVAX

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

EVAX

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Evaxion A/S

Seasonality · EVAX

Insider Activity · EVAX

Congress Trades · EVAX

Investors Holding EVAX

Investors Holding EVAX

Congress Trades · EVAX

Insider Activity · EVAX

Seasonality · EVAX

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Evaxion A/S

Financial Snapshot

Earnings & Dividends

News